



# Review decision – September 2018

Review decision

Published: 28 September 2018

[www.nice.org.uk](http://www.nice.org.uk)

## Decision to move the existing guidance to the static list

We would like to update you on the decision made regarding the review of the existing guidance on TA359; Idelalisib for previously treated chronic lymphocytic leukaemia.

No new evidence was identified that suggests a review of this guidance is necessary.

NICE's Guidance Executive has decided to proceed with this proposal without consultation.

Consequently TA359 will move to the 'static list' of technology appraisals.

[Review decision paper](#)

[Matrix of stakeholders](#)